natgillin/translations-raw huggingface dataset:
It is assumed that the pharmacokinetics of metformin absorption is non-linear. 
Predpostavlja se, da je farmakokinetika absorpcije metformina nelinearna.
- metformin belongs to a group of medicines called biguanides which also help to lower blood sugar by lowering the amount of sugar made in the liver and helping insulin to work more effectively. 
- metformin spada v skupino zdravil, imenovano bigvanidi, ki prav tako pomagajo zniževati vrednost krvnega sladkorja, in sicer tako, da zmanjšajo količino sladkorja, ki nastaja v jetrih, in pomagajo insulinu, da deluje bolj učinkovito.
The most effective method of removing lactate and metformin is haemodialysis. 
Najučinkovitejši način za odstranitev laktata in metformina je hemodializa.
Elderly (≥65 years old) 
Starostniki (bolniki, stari 65 let ali starejši)
Vipdomet is not recommended during breast-feeding since metformin passes into breast milk. 
Uporaba zdravila Vipdomet med dojenjem ni priporočljiva, saj metformin prehaja v materino mleko.
If you have reduced kidney function, your doctor may prescribe a lower dose, which may need to be given as separate tablets of alogliptin and metformin. 
Če imate zmanjšano delovanje ledvic, vam bo morda zdravnik predpisal manjši odmerek, ki ga bo morda treba vzeti kot ločeni tableti alogliptina in metformina.
As Vipdomet contains metformin it must be discontinued at the time of surgery under general, spinal or epidural anesthesia. 
Ker zdravilo Vipdomet vsebuje metformin, je treba jemanje le-tega prekiniti v času operativnega posega pod splošno, spinalno ali epiduralno anestezijo.
Lactic acidosis: 0.03 cases/1,000 patient-years (see section 4.4). 
Laktacidoza: 0,03 primera/1.000 bolnikov-let (glejte poglavje 4.4).
STOP taking Vipdomet and contact a doctor or the nearest hospital immediately if you notice any of the symptoms of the following serious side effects: 
Takoj PRENEHAJTE jemati zdravilo Vipdomet in se obrnite na zdravnika ali najbližjo bolnišnico, če opazite katerega koli od simptomov naslednjih resnih neželenih učinkov:
The effect of Vipdomet on fertility in humans has not been studied. 
Učinek zdravila Vipdomet na plodnost pri ljudeh ni bil raziskan.
The following data are findings from studies performed with alogliptin or metformin individually. 
Naslednji podatki so bili pridobljeni pri študijah, izvedenih posamezno z alogliptinom ali metforminom.
Long-term treatment with metformin has been associated with a decrease in vitamin B12 absorption and appears generally to be without clinical significance. 
Dolgotrajno zdravljenje z metforminom je bilo povezano z zmanjšanjem absorpcije vitamina B12 za kar domnevajo, da na splošno nima kliničnega pomena.
No data are available (see section 4.2 and above). 
Podatkov ni na voljo (glejte poglavje 4.2 in zgoraj).
However, patients should be alerted to the risk of hypoglycaemia especially when used in combination with insulin or pioglitazone. 
Kljub temu pa je bolnike treba opozoriti na možnost pojava hipoglikemije, še posebej, če se zdravilo uporablja v kombinaciji z insulinom ali s pioglitazonom.
The efficacy and safety of the recommended doses of alogliptin and metformin in a subgroup of patients with type 2 diabetes mellitus and ≥65 years old were reviewed and found to be consistent with the profile obtained in patients <65 years old. 
Učinkovitost in varnost priporočenih odmerkov alogliptina in metformina v podskupini bolnikov s sladkorno boleznijo tipa 2, starih 65 let ali starejših, sta bili ponovno pregledani in ugotovljeno je bilo, da sta konsistentni s profilom, pridobljenim pri bolnikih, mlajših od 65 let.
If you are already taking both alogliptin and metformin as single tablets, Vipdomet can replace them in one tablet. 
Če že jemljete alogliptin in metformin v obliki ločenih tablet, jih zdravilo Vipdomet lahko nadomesti z eno samo tableto.
Titanium dioxide (E171) Iron oxide yellow (E172) 
Filmska obloga hipromeloza smukec titanov dioksid (E171) rumeni železov oksid (E172)
Change in clinical status of patients with previously controlled type 2 diabetes mellitus 
Sprememba kliničnega statusa pri bolnikih s predhodno urejeno sladkorno boleznijo tipa 2
In controlled clinical studies, maximum metformin plasma levels (Cmax) did not exceed 4 microgram/mL even at maximum doses. 
V nadzorovanih kliničnih študijah največje koncentracije metformina v plazmi (Cmax) tudi pri največjih odmerkih niso presegle 4 mikrogramov/ml.
It does not stimulate insulin secretion and, therefore, does not produce hypoglycaemia. 
Ne stimulira izločanja insulina, zato ne povzroča hipoglikemije.
What you need to know before you take Vipdomet 
Kaj morate vedeti, preden boste vzeli zdravilo Vipdomet
You should take this medicine with food to reduce your chance of an upset stomach. 
To zdravilo morate jemati skupaj s hrano, saj se tako zmanjša možnost za draženje želodca.
Patients (≥65 years old) with type 2 diabetes mellitus are considered more susceptible to episodes of hypoglycaemia than patients <65 years old. 
Bolniki (stari 65 let ali starejši) s sladkorno boleznijo tipa 2 veljajo za bolj dovzetne za epizode hipoglikemije kot bolniki, mlajši od 65 let.
You may need more frequent blood glucose and kidney function tests, or your doctor may need to adjust the dosage of Vipdomet. 
Morda boste morali pogosteje opravljati preiskave glukoze v krvi in delovanja ledvic, zdravnik pa bo morda moral prilagoditi odmerek zdravila Vipdomet.
In these studies, 696 alogliptin/metformin-treated patients were ≥ 65 years old. 
V teh študijah se z alogliptinom/metforminom zdravilo 696 bolnikov, starih 65 let ali starejših.
Other medicines and Vipdomet 
Druga zdravila in zdravilo Vipdomet
GFR should be assessed before treatment initiation and regularly thereafter (see section 4.2). 
GFR je treba oceniti pred uvedbo zdravljenja, nato pa v rednih presledkih, glejte poglavje 4.2.
Very rare (may affect up to 1 in 10,000 people): - Lactic acidosis (a build-up of lactic acid in the blood) is a very serious side effect that may lead to coma. 
Zelo redki (pojavijo se lahko pri do 1 od 10.000 bolnikov): - Laktacidoza (kopičenje mlečne kisline v krvi) je zelo resen neželeni učinek, ki lahko povzroči komo.
Vipdomet may cause a very rare, but very serious side effect called lactic acidosis, particularly if your kidneys are not working properly. 
Zdravilo Vipdomet lahko povzroči zelo redek, a zelo resen neželeni učinek, imenovan laktacidoza, zlasti če ledvice ne delujejo pravilno.
Diagnostic laboratory findings are decreased blood pH (< 7.35), increased plasma lactate levels (>5 mmol/L) and an increased anion gap and lactate/pyruvate ratio. 
Diagnostični laboratorijski izvidi so zmanjšan pH krvi (<7,35), zvišane ravni laktata v plazmi (>5 mmol/l) in povečana anionska vrzel ter razmerje laktat/piruvat.
In case of suspected symptoms, the patient should stop taking Vipdomet and seek immediate medical attention. 
Ob sumu na simptome mora bolnik prenehati z jemanjem Vipdomet in takoj poiskati zdravniško pomoč.
If you take more tablets than you should, or if someone else or a child takes your medicine, contact or go to your nearest emergency centre straight away. 
Če ste vzeli večji odmerek zdravila Vipdomet kot bi smeli Če ste vzeli več tablet, kot bi smeli, ali pa je vaše zdravilo vzela druga oseba ali otrok, se nemudoma obrnite na najbližji center za nujno medicinsko pomoč ali se odpravite tja.
What Vipdomet is and what it is used for 
Kaj je zdravilo Vipdomet in za kaj ga uporabljamo
Frequency of adverse reactions Alogliptin Metformin Vipdomet 
Pogostnost neželenih učinkov Alogliptin Metformin Vipdomet
Maximum daily dose The maximum recommended daily dose of 25 mg alogliptin should not be exceeded. 
Največji dnevni odmerek Največjega priporočenega dnevnega odmerka 25 mg alogliptina se ne sme preseči.
Vipdomet has no or negligible influence on the ability to drive and use machines. 
Zdravilo Vipdomet nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
What Vipdomet is and what it is used for What you need to know before you take Vipdomet How to take Vipdomet 
Kaj je zdravilo Vipdomet in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Vipdomet Kako jemati zdravilo Vipdomet Možni neželeni učinki
Stop taking Vipdomet and contact a doctor or the nearest hospital immediately if you experience some of the symptoms of lactic acidosis, as this condition may lead to coma. 
Takoj prenehajte jemati zdravilo Vipdomet in se obrnite na zdravnika ali najbližjo bolnišnico, če se pojavijo nekateri od simptomov laktacidoze, saj lahko to stanje vodi v komo.
At the recommended metformin doses and dosing schedules, steady-state plasma concentrations of metformin are reached within 24 to 48 hours and are generally less than 1 microgram/mL. 
Pri priporočenih odmerkih in shemah odmerjanja metformina je plazemska koncentracija v stanju dinamičnega ravnovesja dosežena v 24 do 48 urah in je na splošno manjša od 1 mikrograma/ml.
- if you are taking Vipdomet with insulin or a thiazolidinedione. 
- če jemljete zdravilo Vipdomet skupaj z insulinom ali s tiazolidindionom.
Alogliptin exists predominantly as the (R)-enantiomer (>99%) and undergoes little or no chiral conversion in vivo to the (S)-enantiomer. 
Večina alogliptina je v obliki (R)-enantiomera (>99 %) in je in vivo le v manjši meri ali nič podvržen kiralni pretvorbi v (S)-enantiomer.
In case of dehydration (severe diarrhoea or vomiting, fever, heat, reduced fluid intake) Vipdomet should be temporarily discontinued and contact with a health care professional is recommended. 
V primeru dehidracije (huda driska ali bruhanje, zvišana telesna temperatura ali zmanjšan vnos tekočine) je treba jemanje Vipdomet začasno prekiniti; priporoča se posvet z zdravstvenim delavcem.
Vipdomet with alcohol 
Zdravilo Vipdomet skupaj z alkoholom
After an oral dose of metformin, the maximum plasma concentration (Cmax) is reached in approximately 2.5 hours (Tmax). 
Po peroralnem odmerku metformina je največja plazemska koncentracija (Cmax) dosežena v približno 2,5 ure (Tmax).
A study conducted in seven normal healthy volunteers showed that cimetidine (400 mg twice daily) increased metformin systemic exposure (area under the curve, AUC) by 50% and Cmax by 81%. 
Študija, ki so jo izvedli pri sedmih zdravih prostovoljcih, je pokazala, da uporaba cimetidina (400 mg dvakrat na dan), poveča sistemsko izpostavljenost metforminu (področje pod krivuljo, AUC - area under the curve) za 50 %, vrednost Cmax pa za 81 %.
Vipdomet should not be used in patients with type 1 diabetes mellitus. 
Zdravila Vipdomet se ne sme uporabljati pri bolnikih s sladkorno boleznijo tipa 1.
Stop taking Vipdomet for a short time if you have a condition that may be associated with dehydration (significant loss of body fluids) such as severe vomiting, diarrhoea, fever, exposure to heat or if you drink less fluid than normal. 
Za kratek čas prenehajte jemati zdravilo Vipdomet, če imate stanje, ki je lahko povezano z dehidracijo (znatna izguba telesnih tekočin), kot je hudo bruhanje, driska, zvišana telesna temperatura, izpostavljenost vročini ali če pijete manj tekočine, kot običajno.
Polychlorotrifluoroethylene (PCTFE)/polyvinyl chloride (PVC) blisters with push through aluminium lidding foil. 
Pretisni omoti iz poliklorotrifluoroetilena (PCTFE)/polivinil klorida (PVC), prekriti z aluminijasto pretisno folijo.
Evaluation should include serum electrolytes and ketones, blood glucose and, if indicated, blood pH, lactate, pyruvate and metformin levels. 
Pregled mora vključevati kontrolo elektrolitov in ketonov v serumu, glukoze v krvi in, če je indicirano, pH vrednost krvi ter raven laktata, piruvata in metformina.
The European Medicines Agency has waived the obligation to submit the results of studies with Vipdomet in all subsets of the paediatric population in the treatment of type 2 diabetes mellitus (see section 4.2 for information on paediatric use). 
Evropska agencija za zdravila je začasno odložila zahtevo za predložitev rezultatov študij z zdravilom Vipdomet za eno ali več podskupin pediatrične populacije pri zdravljenju sladkorne bolezni tipa 2 (za podatke o uporabi pri pediatrični populaciji glejte poglavje 4.2).
Vipdomet should not be used during pregnancy. 
Zdravila Vipdomet se med nosečnostjo ne sme uporabljati.
If lactic acidosis is suspected, seek medical attention from a doctor or a hospital. 
Če sumite na laktacidozo, poiščite zdravniško pomoč pri zdravniku ali v bolnišnici.
Metformin is contraindicated in patients with GFR<30 mL/min and should be temporarily discontinued in the presence of conditions that alter renal function (see section 4.3). 
Metformin je kontraindiciran pri bolnikih z GFR<30 ml/min in ga je treba začasno ukiniti, če se pojavijo stanja, ki spremenijo delovanje ledvic, glejte poglavje 4.3.
PHARMACEUTICAL FORM AND CONTENTS Multipack: 196 (2 packs of 98) film-coated tablets. 
FARMACEVTSKA OBLIKA IN VSEBINA Večodmerno pakiranje: 196 (2 škatli po 98) filmsko obloženih tablet.
Specific pharmacokinetic drug interaction studies have not been performed with Vipdomet. 
Specifičnih študij farmakokinetičnih interakcij z zdravilom Vipdomet niso izvedli.
Maximum daily dose is 6.25 mg * Alogliptin dose adjustment is based on a pharmacokinetic study where kidney function was assessed using creatinine clearance (CrCl) levels estimated from the Cockcroft-Gault equation. 
Največji dnevni odmerek je 6,25 mg. *Prilagoditve odmerka alogliptina temeljijo na farmakokinetičnih študijah, kjer so delovanje ledvic ocenili z očistkom kreatinina (CrCl - creatinine clearance), izračunenem po Cockcroft-Gaultovi enačbi.
ACE inhibitors may decrease blood glucose levels. 
Zaviralci ACE lahko zmanjšajo koncentracijo glukoze v krvi.
10 film-coated tablets 14 film-coated tablets 20 film-coated tablets 28 film-coated tablets 56 film-coated tablets 60 film-coated tablets 98 film-coated tablets 112 film-coated tablets 120 film-coated tablets 180 film-coated tablets 196 film-coated tablets 200 film-coated tablets 
10 filmsko obloženih tablet 14 filmsko obloženih tablet 20 filmsko obloženih tablet 28 filmsko obloženih tablet 56 filmsko obloženih tablet 60 filmsko obloženih tablet 98 filmsko obloženih tablet 112 filmsko obloženih tablet 120 filmsko obloženih tablet 180 filmsko obloženih tablet 196 filmsko obloženih tablet 200 filmsko obloženih tablet
Cationic substances that are eliminated by renal tubular secretion (e.g. cimetidine) may interact with metformin by competing for common renal tubular transport systems. 
Kationska zdravila, ki se izločajo z ledvično tubulno sekrecijo (npr. cimetidin), lahko vstopijo v interakcije z metforminom zaradi kompeticije za skupne tubulne transportne sisteme v ledvicah.
Vipdomet is indicated in the treatment of adult patients aged 18 years and older with type 2 diabetes mellitus: 
Zdravilo Vipdomet je indicirano za zdravljenje odraslih bolnikov, starih 18 let in starejših, s sladkorno boleznijo tipa 2:
If you need to have an injection of a contrast medium that contains iodine into your bloodstream, for example in the context of an X-ray or scan, you must stop taking Vipdomet before or at the time of the injection. 
Če vam bodo v krvni obtok injicirali kontrastno sredstvo, ki vsebuje jod, na primer zaradi rentgenskega ali drugega slikanja, morate pred časom injiciranja ali v tem času prenehati z jemanjem zdravila Vipdomet.
Insulin is known to cause hypoglycaemia. 
Znano je, da lahko insulin povzroči hipoglikemijo.
Medicinal products that can acutely impair renal function (such as antihypertensives, diuretics and nonsteroidal anti-inflammatory drugs (NSAIDs)) should be initiated with caution in metformin-treated patients. 
Zdravila, ki lahko akutno okvarijo delovanje ledvic (kot so antihipertenzivi, diuretiki in nesteroidna protivnetna zdravila (NSAID - nonsteroidal anti-inflammatory drugs)), je treba pri bolnikih, ki se zdravijo z metforminom, uvesti previdno.
- alogliptin belongs to a group of medicines called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors). 
- alogliptin spada v skupino zdravil, imenovano zaviralci DPP-4 (zaviralci dipeptidil-peptidaze-4).
- difficulty in breathing - reduced body temperature and heartbeat. 
- splošno slabo počutje s hudo utrujenostjo - težave z dihanjem - znižano telesno temperaturo in počasen srčni utrip.
Common (may affect up to 1 in 10 people): - Symptoms of low blood sugar (hypoglycaemia) may occur when Vipdomet is taken in combination with insulin or sulphonylureas (e.g. glipizide, tolbutamide, glibenclamide). 
Pogosti (pojavijo se lahko pri največ 1 od 10 bolnikov): - Simptomi nizkega krvnega sladkorja (hipoglikemije) se lahko pojavijo, če zdravilo Vipdomet jemljete skupaj z insulinom ali s sulfonilsečninami (npr. glipizid, tolbutamid, glibenklamid).
- Severe and persistent pain in the abdomen (stomach area) which might reach through to your back as well as nausea and vomiting, as it could be a sign of an inflamed pancreas (pancreatitis). 
- Huda in trdovratna bolečina v trebuhu (v predelu želodca), ki lahko izžareva v hrbet, pa tudi siljenje na bruhanje in bruhanje, so lahko znak vnetja trebušne slinavke (pankreatitisa).
Maximum daily dose is 12.5 mg 
Največji dnevni odmerek je 12,5 mg.
Taking Vipdomet in combination with medicines called pioglitazone or insulin can cause too low blood sugar levels (hypoglycaemia), which may affect your ability to drive and use machines. 
Pri jemanju zdravila Vipdomet v kombinaciji s pioglitazonom ali z insulinom se lahko vrednost krvnega sladkorja prekomerno zniža (hipoglikemija), kar lahko vpliva na sposobnost za vožnjo vozil in upravljanje strojev.
A large overdose of metformin or concomitant risks may lead to lactic acidosis. 
Znatno preveliko odmerjanje metformina ali sočasna tveganja lahko privedejo do laktacidoze.
Your doctor may want to reduce your dose of insulin or a thiazolidinedione when you take it together with Vipdomet in order to avoid too low blood sugar (hypoglycaemia). 
Zdravnik se bo morda odločil za zmanjšanje odmerka insulina ali tiazolidindiona, če ga boste jemali skupaj z zdravilom Vipdomet, da prepreči pojav prenizkega krvnega sladkorja (hipoglikemije).
Avoid excessive alcohol intake while taking Vipdomet since this may increase the risk of lactic acidosis - see section “Warnings and precautions”. 
Med jemanjem zdravila Vipdomet ne uživajte čezmernih količin alkohola, saj lahko to poveča tveganje za laktacidozo (glejte poglavje "Opozorila in previdnostni ukrepi").
- in muscle, by modestly increasing insulin sensitivity, improving peripheral glucose uptake and utilisation. 
- v mišicah zmerno poveča občutljivost za insulin, izboljša periferni vnos in izkoriščanje glukoze.
Vipdomet is used to lower blood sugar levels in adults with type 2 diabetes. 
Zdravilo Vipdomet uporabljamo za zniževanje vrednosti krvnega sladkorja pri odraslih s sladkorno boleznijo tipa 2.
A lower dose of insulin may be considered to reduce the risk of hypoglycaemia. 
Razmisliti je treba o zmanjšanju odmerka insulina, da se zmanjša tveganje za hipoglikemijo.
Some medicinal products can adversely affect renal function which may increase the risk of lactic acidosis, e.g. NSAIDs, including selective cyclo-oxygenase (COX) II inhibitors, angiotensinconverting enzyme (ACE) inhibitors, angiotensin II receptor antagonists and diuretics, especially loop diuretics. 
Nekatera zdravila lahko škodljivo vplivajo na delovanje ledvic, kar lahko poveča tveganje za laktacidozo, npr. NSAID, vključno s selektivnimi zaviralci ciklooksigenaze (COX - cyclo-oxygenase) II, zaviralci angiotenzinske konvertaze (ACE - angiotensin-converting enzyme), antagonisti receptorjev angiotenzina II in diuretiki, zlasti diuretiki Henlejeve zanke.
The amount of Vipdomet will vary depending on your condition and the doses you currently take of metformin alone, metformin in combination with pioglitazone, insulin and/or individual tablets of alogliptin and metformin. 
Odmerek zdravila Vipdomet je odvisen od vašega zdravstvenega stanja in odmerkov zdravil, ki jih trenutno jemljete, to je metformina samega, metformina v kombinaciji s pioglitazonom, insulina in/ali posameznih tablet alogliptina in metformina.
- in case of symptoms suggestive of liver injury during Vipdomet therapy. 
- če se pojavijo simptomi poškodbe jeter med jemanjem zdravila Vipdomet.
Higher rates of hypoglycaemia were observed with triple therapy with a thiazolidinedione and metformin and in combination with insulin, as observed with other DPP-4 inhibitors. 
Večji deleži hipoglikemije so bili opaženi pri trotirnem zdravljenju s tiazolidindionom in z metforminom in v kombinaciji z insulinom, tako kot pri drugih zaviralcih DPP-4.
As Vipdomet contains metformin, any patient with type 2 diabetes mellitus previously well controlled on Vipdomet who develops laboratory abnormalities or clinical illness (especially vague and poorly defined illness) should be evaluated promptly for evidence of ketoacidosis or lactic acidosis. 
Ker zdravilo Vipdomet vsebuje metformin, je treba pri vsakem bolniku s sladkorno boleznijo tipa 2, ki je bil predhodno z uporabo zdravila Vipdomet dobro nadzorovan, nato pa so se pojavili nenormalni izvidi laboratorijskih preiskav ali klinične bolezni (še posebej nejasne ali slabo opredeljene bolezni), nemudoma ugotoviti, če ima ketoacidozo ali laktacidozo.
If acidosis of either form occurs, Vipdomet must be stopped immediately and other appropriate corrective measures initiated. 
Če se pojavi acidoza v kateri koli obliki, je treba zdravljenje z zdravilom Vipdomet takoj prekiniti in uvesti ustrezno zdravljenje.
Risk related to metformin 
Tveganja, povezana z metforminom
Lactic acidosis is a medical emergency and must be treated in a hospital. 
Laktacidoza je nujni medicinski primer in jo je treba zdraviti v bolnišnici.
Following oral administration of an 850 mg metformin hydrochloride tablet, the peak plasma concentration was 40% lower, AUC was decreased by 25% and the time to peak plasma concentration (Tmax) was prolonged by 35 minutes. 
Po peroralni uporabi 850-mg tablete metforminijevega klorida je bila največja koncentracija v plazmi manjša za 40 %, vrednost AUC manjša za 25 %, čas do nastopa največje koncentracije v plazmi (Tmax) pa daljši za 35 minut.
Metabolism and nutrition disorders lactic acidosis very rare vitamin B12 deficiency very rare hypoglycaemia common common 
Presnovne in prehranske motnje laktacidoza zelo redki pomanjkanje vitamina B12
Gastrointestinal disorders gastroenteritis common abdominal pain common very common common diarrhoea common very common common vomiting very common common gastritis common gastroesophageal reflux disease common common loss of appetite very common nausea very common acute pancreatitis not known 
Bolezni prebavil gastroenteritis pogosti bolečina v trebuhu pogosti zelo pogosti pogosti driska pogosti zelo pogosti pogosti bruhanje zelo pogosti pogosti gastritis pogosti gastroezofagealni refluks pogosti pogosti izguba apetita zelo pogosti navzea zelo pogosti akutni pankreatitis neznana
Pack sizes of 10, 14, 20, 28, 56, 60, 98, 112, 120, 180, 196, 200 or multipacks containing 196 (2 packs of 98) film-coated tablets. 
Velikost pakiranj: 10, 14, 20, 28, 56, 60, 98, 112, 120, 180, 196, 200 ali večodmerno pakiranje s 196 (2 pakiranji s 98) filmsko obloženimi tabletami.
A single dose of 50 mg alogliptin was administered to 4 groups of patients with varying degrees of renal impairment (CrCl using the Cockcroft-Gault formula): mild (CrCl = >50 to ≤80 mL/min), moderate (CrCl = ≥30 to ≤50 mL/min), severe (CrCl = <30 mL/min) and end-stage renal disease on haemodialysis. 
Enkratni odmerek 50 mg alogliptina so prejele 4 skupine bolnikov z različno stopnjo okvare ledvic (CrCl po enačbi Cockcroft-Gault): blaga (CrCl = >50 do ≤80 ml/min), zmerna (CrCl = ≥30 do ≤50 ml/min), huda (CrCl = <30 ml/min) in končna ledvična odpoved na hemodializi.
Minimal quantities of alogliptin are removed by haemodialysis (approximately 7% of the substance was removed during a 3 hour haemodialysis session). 
Pri hemodializi se odstranijo le majhne količine alogliptina (med 3-urno hemodializo se ga je odstranilo le približno 7 %).
If you forget to take Vipdomet 
Če ste pozabili vzeti zdravilo Vipdomet